Cardiovascular and Soft Tissue Repair Patches Market to Reach $8.58Bn by 2031 at 9.0% CAGR | DataM Intelligence

Rising surgeries and biomaterial advances fuel growth in the cardiovascular and soft tissue repair patches market, forecasted to hit $8.58Bn by 2031.



Cardiovascular and Soft Tissue Repair Patches Market

NEW YORK, NY, UNITED STATES, June 24, 2025 /EINPresswire.com/ -- Market Overview :

The Cardiovascular and Soft Tissue Repair Patches Market is witnessing a steady expansion, driven by advancements in biomaterials and an increasing number of surgical procedures globally. These patches are primarily used in cardiovascular surgeries, hernia repairs, and reconstructive procedures to promote tissue regeneration and reinforce weak anatomical structures. In 2023, the market reached US$ 4.34 billion and is anticipated to grow to US$ 8.58 billion by 2031, registering a CAGR of 9.0% during the forecast period 2024-2031. Growing aging populations, rising prevalence of congenital heart diseases, and greater focus on minimally invasive surgical technologies are bolstering market growth.

> “Cardiovascular and soft tissue repair patches are redefining surgical outcomes by enabling safer, faster healing with advanced biomaterials and regenerative design.”
>
> *DataM Intelligence*

Download Latest Sample Pdf: https://www.datamintelligence.com/download-sample/cardiovascular-and-soft-tissue-repair-patches-market

Market Drivers are ;

Rising incidence of cardiovascular diseases and congenital heart defects

Increasing demand for biologically derived and synthetic tissue repair patches

Growing preference for minimally invasive surgeries

Technological advancements in patch materials for improved compatibility and durability

Government support and reimbursement for cardiac and soft tissue repair procedures

Rising number of trauma and burn injuries requiring surgical patch applications

Surge in hernia repair procedures globally

Key Players in the Market are ;

Leading companies contributing to the innovation and development in this market include:

B. Braun Medical Ltd

W. L. Gore & Associates, Inc.

Edwards Lifesciences Corporation

Baxter International Inc.

Abbott Laboratories

LeMaitre Vascular Inc.

CorMatrix, Inc.

GETINGE Group

Vascudyne, Inc.

Becton, Dickinson and Company

These companies are focusing on expanding their biomaterial portfolios, investing in R&D, and entering strategic collaborations to gain competitive advantage.

Market Segmentation :

By Product Type: Synthetic Patches, Biological Patches

By Application: Cardiovascular Surgery, Hernia Repair, Dural Repair, Vaginal Prolapse, Others

By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics

Latest News – USA

In February 2025, Edwards Lifesciences launched a next-generation bovine pericardial patch designed for pediatric cardiac repairs, receiving early praise for its pliability.

Baxter International announced a new clinical trial in the U.S. evaluating bioengineered patches for large-scale abdominal hernia repairs.

LeMaitre Vascular expanded its surgical patch distribution network across 15 additional states, targeting rural cardiac centers.

Latest News – Japan

In January 2025, Japan's Ministry of Health approved W. L. Gore's cardiovascular patch for national insurance coverage, enhancing access to advanced surgical materials.

CorMatrix, Inc. partnered with a Tokyo-based med-tech distributor to bring its extracellular matrix patches to Japanese hospitals.

Researchers at Osaka University published positive outcomes using biodegradable vascular patches in regenerative therapies.

Recent Key Developments are ;

March 2024: Abbott Laboratories introduced a reinforced PTFE patch for arterial reconstructions.

May 2024: Vascudyne, Inc. completed pre-clinical trials for its fully biological patch derived from cellular scaffolds.

July 2024: Becton, Dickinson and Company expanded its facility in Europe to scale up patch manufacturing.

August 2024: GETINGE Group enhanced its surgical portfolio by acquiring a smaller startup focused on 3D-printed mesh patches.

December 2024: Edwards Lifesciences filed for CE Mark approval for its hybrid collagen-PTFE composite patch.

Conclusion:

The cardiovascular and soft tissue repair patches market is undergoing a transformative phase, supported by the rise in surgical interventions and demand for next-generation biomaterials. Innovations in synthetic and biological patch design are making procedures safer and more effective, particularly in cardiac, vascular, and reconstructive surgeries. North America and Asia-Pacific remain key growth regions owing to high disease prevalence and increasing healthcare expenditure. Moving forward, the market is set to benefit from regulatory support, deeper integration of regenerative medicine, and advancements in materials science that promise quicker healing and fewer complications.

Browse Related Reports :

Distention Systems Market

Liposuction System Market

Sai Kumar
DataM Intelligence 4market Research LLP
+1 877-441-4866
email us here
Visit us on social media:
LinkedIn
X